English (international)
Eesti
Български
Deutsch
Français
Español (Latinoamérica)
Polski
Magyar
Română
Compugen Ltd
Closed
1.83
Overview
Share price change
24h
Min
1.83
Max
1.86
Income | 2.6M -7.3M |
|---|---|
Sales | -31M 2.6M |
EPS | -0.08 |
Profit margin | -283.978 |
EBITDA | -8.5M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +118.58 upside |
Next Earnings | 5 lis 2024 |
|---|
Market Cap | 47M 640M |
|---|---|
Previous open | 1.83 |
Previous close | 1.83 |
Technical Score
By Trading Central
Confidence
Strong Bearish Evidence
Compugen Ltd Chart
Related News
Peer Comparison
Price change
Compugen Ltd Forecast
Price Target
By TipRanks
118.58% upside
12 Months Forecast
Average 4 USD 118.58%
High 4 USD
Low 4 USD
Based on 3 Wall Street analysts offering 12 month price targets forCompugen Ltd - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
EBITDA
Operating profit
$
About Compugen Ltd
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
